Reviews21 August 2012
A Systematic Review and Meta-analysis
    Author, Article, and Disclosure Information
    Background:

    Statins have uncertain benefits in persons with chronic kidney disease (CKD) because individual trials may have insufficient power to determine whether treatment effects differ with severity of CKD.

    Purpose:

    To summarize the benefits and harms of statin therapy for adults with CKD and examine whether effects of statins vary by stage of kidney disease.

    Data Sources:

    Cochrane and EMBASE databases (inception to February 2012).

    Study Selection:

    Randomized trials comparing the effects of statins with placebo, no treatment, or another statin on mortality and cardiovascular outcomes.

    Data Extraction:

    Two independent reviewers extracted data and assessed risk of bias.

    Data Synthesis:

    Eighty trials comprising 51 099 participants compared statin with placebo or no treatment. Treatment effects varied with stage of CKD. Moderate- to high-quality evidence indicated that statins reduced all-cause mortality (relative risk [RR], 0.81 [95% CI, 0.74 to 0.88]), cardiovascular mortality (RR, 0.78 [CI, 0.68 to 0.89]), and cardiovascular events (RR, 0.76 [CI, 0.73 to 0.80]) in persons not receiving dialysis. Moderate- to high-quality evidence indicated that statins had little or no effect on all-cause mortality (RR, 0.96 [CI, 0.88 to 1.04]), cardiovascular mortality (RR, 0.94 [CI, 0.82 to 1.07]), or cardiovascular events (RR, 0.95 [CI, 0.87 to 1.03]) in persons receiving dialysis. Effects of statins in kidney transplant recipients were uncertain. Statins had little or no effect on cancer, myalgia, liver function, or withdrawal from treatment, although adverse events were evaluated systematically in fewer than half of the trials.

    Limitation:

    There was a reliance on post hoc subgroup data for earlier stages of CKD.

    Conclusion:

    Statins decrease mortality and cardiovascular events in persons with early stages of CKD, have little or no effect in persons receiving dialysis, and have uncertain effects in kidney transplant recipients.

    Primary Funding Source:

    None.

    References

    • 1. Foley RNParfrey PSSarnak MJClinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis1998;32:S112-9. [PMID: 9820470] CrossrefMedlineGoogle Scholar
    • 2. de Jager DJGrootendorst DCJager KJvan Dijk PCTomas LMAnsell Det alCardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA2009;302:1782-9. [PMID: 19861670] CrossrefMedlineGoogle Scholar
    • 3. Baigent CKeech AKearney PMBlackwell LBuck GPollicino Cet alCholesterol Treatment Trialists' (CTT) CollaboratorsEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366:1267-78. [PMID: 16214597] CrossrefMedlineGoogle Scholar
    • 4. Chonchol MCook TKjekshus JPedersen TRLindenfeld JSimvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis2007;49:373-82. [PMID: 17336698] CrossrefMedlineGoogle Scholar
    • 5. Kendrick JShlipak MGTargher GCook TLindenfeld JChonchol MEffect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis2010;55:42-9. [PMID: 19932541] CrossrefMedlineGoogle Scholar
    • 6. Ridker PMMacFadyen JCressman MGlynn RJEfficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol2010;55:1266-73. [PMID: 20206456] MedlineGoogle Scholar
    • 7. Wanner CKrane VMärz WOlschewski MMann JFRuf Get alGerman Diabetes and Dialysis Study InvestigatorsAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med2005;353:238-48. [PMID: 16034009] CrossrefMedlineGoogle Scholar
    • 8. Fellström BCJardine AGSchmieder REHoldaas HBannister KBeutler Jet alAURORA Study GroupRosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med2009;360:1395-407. [PMID: 19332456] CrossrefMedlineGoogle Scholar
    • 9. Green DRoberts PRNew DIKalra PASudden cardiac death in hemodialysis patients: an in-depth review. Am J Kidney Dis2011;57:921-9. [PMID: 21496983] CrossrefMedlineGoogle Scholar
    • 10. United States Renal Data System. United States Renal Data System 2010 Annual Data Report. Volume One: Atlas of Chronic Kidney Disease in the United States, and Volume Two: End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010. Google Scholar
    • 11. Strippoli GFNavaneethan SDJohnson DWPerkovic VPellegrini FNicolucci Aet alEffects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ2008;336:645-51. [PMID: 18299289] CrossrefMedlineGoogle Scholar
    • 12. Baigent CLandray MJReith CEmberson JWheeler DCTomson Cet alSHARP InvestigatorsThe effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377:2181-92. [PMID: 21663949] CrossrefMedlineGoogle Scholar
    • 13. Koren MJDavidson MHWilson DJFayyad RSZuckerman AReed DPALLIANCE InvestigatorsFocused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis2009;53:741-50. [PMID: 19216014] CrossrefMedlineGoogle Scholar
    • 14. Colhoun HMBetteridge DJDurrington PNHitman GANeil HALivingstone SJet alCARDS InvestigatorsEffects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis2009;54:810-9. [PMID: 19540640] CrossrefMedlineGoogle Scholar
    • 15. Nakamura HMizuno KOhashi YYoshida THirao KUchida YMEGA Study GroupPravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis2009;206:512-7. [PMID: 19423108] CrossrefMedlineGoogle Scholar
    • 16. U.S. Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee Meeting: Clinical Briefing Document. Silver Spring, MD: U.S. Food and Drug Administration; 2011. Accessed at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm277649.pdf on 3 November 2011. Google Scholar
    • 17. U.S. Food and Drug Administration. Vytorin (ezetimibe/simvastatin) tablet Web site. Silver Spring, MD: U.S. Food and Drug Administration; 2012. Accessed at www.fda.gov/Safety/MedWatch/SafetyInformation/ucm208609.htm on 1 March 2012. Google Scholar
    • 18. Navaneethan SDNigwekar SUPerkovic VJohnson DWCraig JCStrippoli GFHMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev2009;:CD004289. [PMID: 19588351] MedlineGoogle Scholar
    • 19. Navaneethan SDPansini FPerkovic VManno CPellegrini FJohnson DWet alHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev2009;:CD007784. [PMID: 19370693] MedlineGoogle Scholar
    • 20. Navaneethan SDPerkovic VJohnson DWNigwekar SUCraig JCStrippoli GFHMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev2009;:CD005019. [PMID: 19370615] MedlineGoogle Scholar
    • 21. National Kidney FoundationK/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis2002;39:S1-266. [PMID: 11904577] MedlineGoogle Scholar
    • 22. Scanferla FToffoletto PPRoncali DBazzato GAssociated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects [Letter]. Am J Hypertens1991;4:868. [PMID: 1747221] CrossrefMedlineGoogle Scholar
    • 23. Hommel EAndersen PGall MANielsen FJensen BRossing Pet alPlasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia1992;35:447-51. [PMID: 1521727] CrossrefMedlineGoogle Scholar
    • 24. Mori YTsuruoka AEffect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus. Journal of the Japan Diabetes Society1992;35:265-8. Google Scholar
    • 25. Martinez Hernandez BEPersaud JWVarghese ZMoorhead JFLow-dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrol Dial Transplant1993;8:637-41. [PMID: 8396749] MedlineGoogle Scholar
    • 26. Nielsen SSchmitz OMøller NPørksen NKlausen ICAlberti KGet alRenal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia1993;36:1079-86. [PMID: 8243858] CrossrefMedlineGoogle Scholar
    • 27. Thomas MEHarris KPRamaswamy CHattersley JMWheeler DCVarghese Zet alSimvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int1993;44:1124-9. [PMID: 8264145] CrossrefMedlineGoogle Scholar
    • 28. Aranda Arcas JLSánchez RGuijarro CAraque APulido FPraga Met al[Effect of pravastatin on hypercholesterolemia associated with proteinuria]. An Med Interna1994;11:523-7. [PMID: 7654898] MedlineGoogle Scholar
    • 29. Arnadottir MEriksson LOGermershausen JIThysell HLow-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron1994;68:57-62. [PMID: 7991041] CrossrefMedlineGoogle Scholar
    • 30. Lam KSCheng IKJanus EDPang RWCholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia1995;38:604-9. [PMID: 7489845] CrossrefMedlineGoogle Scholar
    • 31. Lintott CJScott RSBremer JMShand BIFluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. Am J Cardiol1995;76:97A-101A. [PMID: 7604809] CrossrefMedlineGoogle Scholar
    • 32. Zhang AVertommen JVan Gaal LDe Leeuw IEffects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Res Clin Pract1995;29:189-94. [PMID: 8591712] CrossrefMedlineGoogle Scholar
    • 33. Katznelson SWilkinson AHKobashigawa JAWang XMChia DOzawa Met alThe effect of pravastatin on acute rejection after kidney transplantation—a pilot study. Transplantation1996;61:1469-74. [PMID: 8633373] CrossrefMedlineGoogle Scholar
    • 34. Rayner BLByrne MJvan Zyl Smit RA prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol1996;46:219-24. [PMID: 8905205] MedlineGoogle Scholar
    • 35. Paczek LBill MWyzgał JGaciong ZGradowska LJuskowa Jet al[The effect of hypolipidemia treatment on the function of kidney transplanted from cadavers]. Pol Arch Med Wewn1997;97:144-56. [PMID: 9312763] MedlineGoogle Scholar
    • 36. Walker RJSutherland WHWalker HLMacMahon SRobson RAEffect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrol Dial Transplant1997;12:87-92. [PMID: 9027779] CrossrefMedlineGoogle Scholar
    • 37. Tonolo GCiccarese MBrizzi PPuddu LSecchi GCalvia Pet alReduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care1997;20:1891-5. [PMID: 9405913] CrossrefMedlineGoogle Scholar
    • 38. Veličković-Radovanović RAvramović MMalobabić ZDjordjevic VKostic SMitić BTherapeutic effects of simvastatin on hyperlipidemia in uraemic patients on CAPD [Abstract]. Nephrol Dial Transplant1997;12:A187. MedlineGoogle Scholar
    • 39. Melchor JLGracida CTreatment of hypercholesterolemia with fluvastatin in kidney transplant patients. Transplant Proc1998;30:2054. [PMID: 9723390] CrossrefMedlineGoogle Scholar
    • 40. Imai YSuzuki HSaito TTsuji IAbe KSaruta TThe effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group. Clin Exp Hypertens1999;21:1345-55. [PMID: 10574417] CrossrefMedlineGoogle Scholar
    • 41. Lepre FRigby RHawley CSaltissi DBrown AWalsh ZA double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. Clin Transplant1999;13:520-5. [PMID: 10617243] CrossrefMedlineGoogle Scholar
    • 42. Buemi MAllegra ACorica FAloisi CGiacobbe MPettinato Get alEffect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther2000;67:427-31. [PMID: 10801253] CrossrefMedlineGoogle Scholar
    • 43. Fried LFForrest KYEllis DChang YSilvers NOrchard TJLipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications2001;15:113-9. [PMID: 11358679] CrossrefMedlineGoogle Scholar
    • 44. Hausberg MKosch MStam FHeidenreich SKisters KRahn KHet alEffect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int2001;59:1473-9. [PMID: 11260410] CrossrefMedlineGoogle Scholar
    • 45. Kasiske BLHeim-Duthoy KLSinger GGWatschinger BGermain MJBastani BThe effects of lipid-lowering agents on acute renal allograft rejection. Transplantation2001;72:223-7. [PMID: 11477342] CrossrefMedlineGoogle Scholar
    • 46. Renders LMayer-Kadner IKoch CSchärffe SBurkhardt KVeelken Ret alEfficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant2001;16:141-6. [PMID: 11209008] CrossrefMedlineGoogle Scholar
    • 47. Sahu KSharma RGupta AGulati SAgarwal DKumar Aet alEffect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clin Transplant2001;15:173-5. [PMID: 11389707] CrossrefMedlineGoogle Scholar
    • 48. Santos AFKeitel EBittar AENeumann JFuchs FDGoldani JCet alSafety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. Transplant Proc2001;33:1194-5. [PMID: 11267254] CrossrefMedlineGoogle Scholar
    • 49. Holdaas HJardine AGWheeler DCBrekke IBConlon PJFellstrøm Bet alEffect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int2001;60:1990-7. [PMID: 11703619] CrossrefMedlineGoogle Scholar
    • 50. Chang JWYang WSMin WKLee SKPark JSKim SBEffects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis2002;39:1213-7. [PMID: 12046033] CrossrefMedlineGoogle Scholar
    • 51. Cofan FZambon DLaguna JCCasals ERos ECofan Met alPravastatin improves low-density lipoprotein oxidation in renal transplantation. Transplant Proc2002;34:389-91. [PMID: 11959339] CrossrefMedlineGoogle Scholar
    • 52. Gheith OA, Sobh MA, Mohamed Kel-S, El-Baz MA, El-Husseini F, Gazarin SS, et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron. 2002;91:612-9. [PMID: 12138263] Google Scholar
    • 53. Harris KPWheeler DCChong CCAtorvastatin in CAPD Study InvestigatorsContinuous ambulatory peritoneal dialysis. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int2002;61:1469-74. [PMID: 11918754] CrossrefMedlineGoogle Scholar
    • 54. Ichihara AHayashi MRyuzaki MHanda MFurukawa TSaruta TFluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant2002;17:1513-7. [PMID: 12147804] CrossrefMedlineGoogle Scholar
    • 55. Nakamura TUshiyama CHirokawa KOsada SInoue TShimada Net alEffect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant2002;17:798-802. [PMID: 11981066] CrossrefMedlineGoogle Scholar
    • 56. Saltissi DMorgan CRigby RJWesthuyzen JSafety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis2002;39:283-90. [PMID: 11840368] CrossrefMedlineGoogle Scholar
    • 57. Samuelsson OAttman POKnight-Gibson CMulec HWeiss LAlaupovic PFluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. Am J Kidney Dis2002;39:67-75. [PMID: 11774104] CrossrefMedlineGoogle Scholar
    • 58. Holdaas HFellström BJardine AGHolme INyberg GFauchald Pet alAssessment of LEscol in Renal Transplantation (ALERT) Study InvestigatorsEffect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet2003;361:2024-31. [PMID: 12814712] CrossrefMedlineGoogle Scholar
    • 59. Bianchi SBigazzi RCaiazza ACampese VMA controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis2003;41:565-70. [PMID: 12612979] CrossrefMedlineGoogle Scholar
    • 60. Collins RArmitage JParish SSleigh PPeto RHeart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361:2005-16. [PMID: 12814710] CrossrefMedlineGoogle Scholar
    • 61. Lins RLMatthys KEBilliouw JMDratwa MDupont PLameire NHet alLipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol2004;62:287-94. [PMID: 15524059] CrossrefMedlineGoogle Scholar
    • 62. Tonelli MIsles CCurhan GCTonkin APfeffer MAShepherd Jet alEffect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation2004;110:1557-63. [PMID: 15364796] CrossrefMedlineGoogle Scholar
    • 63. Asselbergs FWDiercks GFHillege HLvan Boven AJJanssen WMVoors AAet alPrevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) InvestigatorsEffects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation2004;110:2809-16. [PMID: 15492322] CrossrefMedlineGoogle Scholar
    • 64. Vernaglione LCristofano CMuscogiuri PChimienti SDoes atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis2004;43:471-8. [PMID: 14981605] CrossrefMedlineGoogle Scholar
    • 65. Yasuda GKuji THasegawa KOgawa NShimura GAndo Det alSafety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Ren Fail2004;26:411-8. [PMID: 15462110] CrossrefMedlineGoogle Scholar
    • 66. Di Lullo LAddesse RComegna CFirmi GGalderisi CIannacci GRet alEffects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Adv Ther2005;22:601-12. [PMID: 16510377] CrossrefMedlineGoogle Scholar
    • 67. Diepeveen SHVerhoeven GWVan Der Palen JDikkeschei LDVan Tits LJKolsters Get alEffects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. J Intern Med2005;257:438-45. [PMID: 15836660] CrossrefMedlineGoogle Scholar
    • 68. Dornbrook-Lavender KAJoy MSDenu-Ciocca CJChin HHogan SLPieper JAEffects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy2005;25:335-44. [PMID: 15843280] CrossrefMedlineGoogle Scholar
    • 69. Lee TMLin MSTsai CHChang NCAdd-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney Int2005;68:779-87. [PMID: 16014056] CrossrefMedlineGoogle Scholar
    • 70. Lemos PASerruys PWde Feyter PMercado NFGoedhart DSaia Fet alLong-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). Am J Cardiol2005;95:445-51. [PMID: 15695126] CrossrefMedlineGoogle Scholar
    • 71. Nakamura TSugaya TKawagoe YUeda YOsada SKoide HEffect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care2005;28:2728-32. [PMID: 16249547] CrossrefMedlineGoogle Scholar
    • 72. Verma ARanganna KMReddy RSVerma MGordon NFEffect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol2005;96:1290-2. [PMID: 16253600] CrossrefMedlineGoogle Scholar
    • 73. Stegmayr BGBrännström MBucht SCrougneau VDimeny EEkspong Aet alNediat Study GroupLow-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scand J Urol Nephrol2005;39:489-97. [PMID: 18161210] CrossrefMedlineGoogle Scholar
    • 74. Baigent CLandray MLeaper CAltmann PArmitage JBaxter Aet alFirst United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis2005;45:473-84. [PMID: 15754269] CrossrefMedlineGoogle Scholar
    • 75. Vareesangthip K, Laouthaiwattana P, Hanlakorn P, Suwannaton L, Larpkitkachorn R, Chuawattana D, et al. Effects of simvastatin on the kinetics of erythrocyte sodium lithium countertransport and C-reactive protein in hemodialysis patients [Abstract]. J Am Soc Nephrol. 2005;16:276A. Abstract TH-PO726. Google Scholar
    • 76. Ahmadi FI, Eslami K, Maziar S, Lessan-Pezeshki M, Khatami MR, Mahdavi-Mazdeh M, et al. Effect of lovastatin on high-sensitivity C-reactive protein and hemoglobin in hemodialysis patients [Abstract]. Nephrol Dial Transplant. 2006;21(Suppl 4):iv229. Abstract SP637. Google Scholar
    • 77. Goicoechea Mde Vinuesa SGLahera VCachofeiro VGómez-Campderá FVega Aet alEffects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol2006;17:S231-5. [PMID: 17130267] CrossrefMedlineGoogle Scholar
    • 78. Nakamura TSugaya TKawagoe YSuzuki TInoue TNode KEffect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. Am J Nephrol2006;26:82-6. [PMID: 16534182] CrossrefMedlineGoogle Scholar
    • 79. Panichi VPaoletti SMantuano EManca-Rizza GFilippi CSanti Set alIn vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant2006;21:337-44. [PMID: 16249194] CrossrefMedlineGoogle Scholar
    • 80. Dummer CDThome' FSZingano BLindoso AVeronese FVAcute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease. J Nephrol2008;21:900-8. [PMID: 19034875] MedlineGoogle Scholar
    • 81. Sawara YTakei TUchida KOgawa TYoshida TTsuchiya Ket alEffects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Intern Med2008;47:1505-10. [PMID: 18758125] CrossrefMedlineGoogle Scholar
    • 82. Serón DOppenheimer FPallardó LMLauzurica RErrasti PGomez-Huertas Eet alFluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial. Transplantation2008;86:82-7. [PMID: 18622282] CrossrefMedlineGoogle Scholar
    • 83. Tokunaga M, Tamura M, Kabashima N, Serino R, Shibata T, Matsumoto M, et al. Beneficial effects of pitavastatin on albuminuria and renal function in essential hypertensive patients with chronic kidney disease [Abstract]. J Am Soc Nephrol. 2008;19:307A. Abstract TH-PO875. Google Scholar
    • 84. Tse KCYung STang CSTam SLai KNChan TMAtorvastatin at conventional dose did not reduce C-reactive protein in patients on peritoneal dialysis [Letter]. J Nephrol2008;21:283. [PMID: 18587714] MedlineGoogle Scholar
    • 85. Burmeister JEMiltersteiner DRCampos BMRosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein. J Nephrol2009;22:83-9. [PMID: 19229822] MedlineGoogle Scholar
    • 86. Sharif ARavindran VMoore RDunseath GLuzio SOwens Det alThe effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients. Am J Transplant2009;9:1439-45. [PMID: 19459810] CrossrefMedlineGoogle Scholar
    • 87. Ruggenenti PPerna ATonelli MLoriga GMotterlini NRubis Net alESPLANADE Study GroupEffects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. Clin J Am Soc Nephrol2010;5:1928-38. [PMID: 20671225] CrossrefMedlineGoogle Scholar
    • 88. Fassett RGCoombes JSPackham DFairley KFKincaid-Smith PEffect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scand J Urol Nephrol2010;44:56-61. [PMID: 20034362] CrossrefMedlineGoogle Scholar
    • 89. Fassett RGRobertson IKBall MJGeraghty DPCoombes JSEffect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial. Atherosclerosis2010;213:218-24. [PMID: 20810109] CrossrefMedlineGoogle Scholar
    • 90. Renke MTylicki LRutkowski PNeuwelt ALarczyński WZietkiewicz Met alAtorvastatin improves tubular status in non-diabetic patients with chronic kidney disease—placebo controlled, randomized, cross-over study. Acta Biochim Pol2010;57:547-52. [PMID: 21079818] MedlineGoogle Scholar
    • 91. Gupta AKChang CLDahlof BPoulter NRSever PSCardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [Abstract]. J Hum Hypertens2011;25:633-4. Google Scholar
    • 92. Han SHKang EWYoon SJYoon HSLee HCYoo THet alCombined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis. Nephrol Dial Transplant2011;26:3722-8. [PMID: 21385862] CrossrefMedlineGoogle Scholar
    • 93. Baigent CLandray MJReith CEmberson JWheeler DCTomson Cet alSHARP InvestigatorsThe effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377:2181-92. [PMID: 21663949] CrossrefMedlineGoogle Scholar
    • 94. Castelao AMGriñó JMAndrés EGilvernet SSerón DCastiñeiras MJet alHMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation. Transplant Proc1993;25:1043-6. [PMID: 8442035] MedlineGoogle Scholar
    • 95. Raiola PManzo MSaggese AComparison of atorvastatin (ATV) with fluvastatin (FLV) in renal transplant patients with dyslipoproteinemia [Abstract]. J Am Soc Nephrol1998;9:693A. Google Scholar
    • 96. Vergoulas GMiserlis GGakis DImvrios GPapagiannis APapanikolaou Vet alLovastatin (L) versus fluvastatin (F) in the treatment of hypercholesterolemic (HCH) renal transplant recipients (RTR) [Abstract]. Nephrol Dial Transplant1999;14:A312. Google Scholar
    • 97. Celik AUnsal AMutaf IHabif SOk EBayindir OWhich dosage of simvastatin in renal transplant patients? [Letter]. Nephron2000;84:81-2. [PMID: 10644914] CrossrefMedlineGoogle Scholar
    • 98. Tuncer MSüleymanlar GErsoy FFYakupoğlu GComparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplant Proc2000;32:622-5. [PMID: 10812143] CrossrefMedlineGoogle Scholar
    • 99. van den Akker JMBredie SJDiepenveen SHvan Tits LJStalenhoef AFvan Leusen RAtorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol2003;16:238-44. [PMID: 12768071] MedlineGoogle Scholar
    • 100. Pedersen TRFaergeman OKastelein JJOlsson AGTikkanen MJHolme Iet alIncremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study GroupHigh-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA2005;294:2437-45. [PMID: 16287954] CrossrefMedlineGoogle Scholar
    • 101. Shepherd JKastelein JJBittner VDeedwania PBreazna ADobson Set alTNT (Treating to New Targets) InvestigatorsIntensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol2008;51:1448-54. [PMID: 18402899] CrossrefMedlineGoogle Scholar
    • 102. Rutter MKPrais HRCharlton-Menys VGittins MRoberts CDavies RRet alProtection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin. Diabet Med2011;28:100-8. [PMID: 21166851] CrossrefMedlineGoogle Scholar
    • 103. Briel MSchwartz GGThompson PLde Lemos JABlazing MAvan Es GAet alEffects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA2006;295:2046-56. [PMID: 16670413] CrossrefMedlineGoogle Scholar
    • 104. Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration; 2011. Accessed at www.cochrane-handbook.org on 7 June 2012. Google Scholar
    • 105. DerSimonian RLaird NMeta-analysis in clinical trials. Control Clin Trials1986;7:177-88. [PMID: 3802833] CrossrefMedlineGoogle Scholar
    • 106. Harbord RMEgger MSterne JAA modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med2006;25:3443-57. [PMID: 16345038] CrossrefMedlineGoogle Scholar
    • 107. van Houwelingen HCArends LRStijnen TAdvanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med2002;21:589-624. [PMID: 11836738] CrossrefMedlineGoogle Scholar
    • 108. Guyatt GHOxman ADVist GEKunz RFalck-Ytter YAlonso-Coello Pet alGRADE Working GroupGRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924-6. [PMID: 18436948] CrossrefMedlineGoogle Scholar
    • 109. Anavekar NSMcMurray JJVelazquez EJSolomon SDKober LRouleau JLet alRelation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med2004;351:1285-95. [PMID: 15385655] CrossrefMedlineGoogle Scholar
    • 110. Chan JHui RLLevin EDifferential association between statin exposure and elevated levels of creatine kinase. Ann Pharmacother2005;39:1611-6. [PMID: 16160000] CrossrefMedlineGoogle Scholar
    • 111. Di Angelantonio EChowdhury RSarwar NAspelund TDanesh JGudnason VChronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ2010;341:c4986. [PMID: 20884698] CrossrefMedlineGoogle Scholar
    • 112. Herzog CAMa JZCollins AJPoor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med1998;339:799-805. [PMID: 9738087] CrossrefMedlineGoogle Scholar
    • 113. Kasiske BLMaclean JRSnyder JJAcute myocardial infarction and kidney transplantation. J Am Soc Nephrol2006;17:900-7. [PMID: 16481414] CrossrefMedlineGoogle Scholar
    • 114. Trivedi HXiang QKlein JPRisk factors for non-fatal myocardial infarction and cardiac death in incident dialysis patients. Nephrol Dial Transplant2009;24:258-66. [PMID: 18682489] CrossrefMedlineGoogle Scholar
    • 115. Weiner DETabatabai STighiouart HElsayed EBansal NGriffith Jet alCardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis2006;48:392-401. [PMID: 16931212] CrossrefMedlineGoogle Scholar
    • 116. Wetmore JBShireman TIThe ABCs of cardioprotection in dialysis patients: a systematic review. Am J Kidney Dis2009;53:457-66. [PMID: 19022545] CrossrefMedlineGoogle Scholar
    • 117. Strippoli GFCraig JCSchena FPThe number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol2004;15:411-9. [PMID: 14747388] CrossrefMedlineGoogle Scholar
    • 118. Baigent CBurbury KWheeler DPremature cardiovascular disease in chronic renal failure. Lancet2000;356:147-52. [PMID: 10963260] CrossrefMedlineGoogle Scholar
    • 119. Stevens KKJardine AGSHARP: a stab in the right direction in chronic kidney disease. Lancet2011;377:2153-4. [PMID: 21663950] CrossrefMedlineGoogle Scholar
    • 120. Palmer SCHayen AMacaskill PPellegrini FCraig JCElder GJet alSerum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA2011;305:1119-27. [PMID: 21406649] CrossrefMedlineGoogle Scholar
    • 121. Phrommintikul AHaas SJElsik MKrum HMortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet2007;369:381-8. [PMID: 17276778] CrossrefMedlineGoogle Scholar
    • 122. Ridker PMDanielson EFonseca FAGenest JGotto AMKastelein JJet alJUPITER Study GroupRosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med2008;359:2195-207. [PMID: 18997196] CrossrefMedlineGoogle Scholar
    • 123. Boutron IDutton SRavaud PAltman DGReporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA2010;303:2058-64. [PMID: 20501928] CrossrefMedlineGoogle Scholar